Entero Healthcare Solutions Limited — Q4 FY26
Entero Healthcare delivered a strong FY26, with revenue of ₹6,591 crore growing 31.5% YoY on a like-for-like basis, driven by 15.6% organic growth and 16% inorganic contribution.
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
Full-year like-to-like revenue growth of 30%
Management confirmed on track to deliver 30% like-to-like revenue growth for FY26, implying ~35% growth in Q4.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY26
Full-year EBITDA margin above 4%
EBITDA margin guidance of north of 4% for FY26, requiring Q4 margin of ~4.5% to achieve.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY26
Operating cash flow of ₹100 crore for FY26
OCF guidance of ₹100 crore for full year, with Q4 expected to generate over ₹100 crore given 9-month OCF of -₹8 crore.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1